Hospital
Forrest County General Hospital
Forrest County General Hospital was paid $21.66M by Medicaid between Jan 2018 and Dec 2024, across 233 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoFORREST COUNTY GENERAL HOSPITAL
PICAYUNE, MS 39466
PICAYUNE, MS 39466
33aNPI1053350462assigned 06/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.66M
24GClaims596,298
24DCodes billed233
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#24 of 77
Median peer was paid$8.23M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HESTER, BEN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 82,901 | $2.91M | |
| 2019 | 81,836 | $3.05M | |
| 2020 | 63,888 | $2.43M | |
| 2021 | 78,727 | $2.95M | |
| 2022 | 99,728 | $3.48M | |
| 2023 | 106,604 | $3.87M | |
| 2024incomplete | 82,614 | $2.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 21,210 | 18,312 | $4.07M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 13,764 | 11,760 | $2.96M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 19,705 | 17,310 | $2.93M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.3% | 11,705 | 9,750 | $1.14M |
| G0378 | Hospital observation service, per hour | 4.1% | 2,549 | 1,869 | $888K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 17,783 | 4,111 | $656K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 3,286 | 2,957 | $526K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 6,242 | 5,464 | $368K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.6% | 4,454 | 2,574 | $351K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 3,945 | 3,069 | $348K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 10,345 | 8,735 | $325K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 7,555 | 6,695 | $320K |
221 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 2,625 | $271K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 6,768 | $268K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.2% | 7,789 | $254K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 9,570 | $254K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 1,544 | $253K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 8,350 | $253K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 12,084 | $252K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.2% | 1,053 | $249K |
| 87634 | 1.1% | 5,506 | $242K | |
| 80053 | Comprehensive metabolic panel | <1% | 32,040 | $212K |
| 86900 | <1% | 3,723 | $202K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,350 | $185K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 38,062 | $178K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,882 | $165K |
| 74018 | <1% | 3,140 | $156K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,444 | $149K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,528 | $143K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,530 | $137K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,520 | $126K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,525 | $125K |
| 76801 | <1% | 1,645 | $110K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 40,645 | $96K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,533 | $89K |
| 86850 | <1% | 3,397 | $87K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,379 | $84K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,098 | $78K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,146 | $76K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,993 | $76K |
| 80074 | <1% | 2,176 | $75K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 895 | $71K |
| 86901 | <1% | 3,734 | $64K | |
| 73630 | <1% | 1,479 | $63K | |
| 97162 | <1% | 1,274 | $55K | |
| 83880 | <1% | 3,843 | $54K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 723 | $53K |
| 84484 | <1% | 8,209 | $52K | |
| 80061 | Lipid panel | <1% | 5,367 | $50K |
| 73610 | <1% | 1,003 | $48K | |
| 88142 | <1% | 2,676 | $45K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,176 | $44K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 621 | $44K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,148 | $40K |
| 81001 | <1% | 18,912 | $39K | |
| 73562 | <1% | 943 | $38K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 431 | $38K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,811 | $37K |
| 82553 | <1% | 6,862 | $34K | |
| 73030 | <1% | 958 | $34K | |
| 81025 | <1% | 5,850 | $34K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 727 | $34K |
| 76830 | Ultrasound, transvaginal | <1% | 499 | $33K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 503 | $32K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,796 | $30K |
| 87430 | <1% | 2,460 | $30K | |
| 73130 | <1% | 679 | $30K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,212 | $29K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 391 | $27K |
| 82550 | <1% | 8,538 | $26K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,927 | $26K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 264 | $25K |
| 97165 | <1% | 631 | $25K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 689 | $22K |
| 87428 | <1% | 385 | $22K | |
| 84702 | <1% | 2,021 | $22K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 801 | $21K |
| 83690 | <1% | 5,220 | $21K | |
| 72110 | <1% | 379 | $21K | |
| 87040 | <1% | 2,752 | $20K | |
| 84439 | <1% | 2,721 | $18K | |
| 87081 | <1% | 3,347 | $18K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 487 | $18K |
| 73110 | <1% | 389 | $17K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 299 | $17K |
| 83605 | <1% | 3,257 | $16K | |
| 86762 | <1% | 1,304 | $15K | |
| 87186 | <1% | 2,532 | $15K | |
| 87077 | <1% | 2,605 | $14K | |
| 73564 | <1% | 242 | $14K | |
| 36600 | <1% | 534 | $14K | |
| 87420 | <1% | 1,167 | $13K | |
| 72100 | <1% | 232 | $13K | |
| 85610 | <1% | 5,201 | $12K | |
| 85379 | <1% | 2,277 | $12K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 68 | $11K |
| 85730 | <1% | 3,335 | $10K | |
| 93971 | <1% | 259 | $10K | |
| 86592 | <1% | 2,940 | $10K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 167 | $9K |
| 83735 | <1% | 2,972 | $9K | |
| 12001 | <1% | 82 | $9K | |
| 82962 | <1% | 5,214 | $9K | |
| 87150 | <1% | 424 | $8K | |
| 82803 | <1% | 794 | $8K | |
| 82728 | <1% | 1,016 | $8K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 123 | $7K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 30 | $7K |
| 82607 | <1% | 851 | $7K | |
| 73502 | <1% | 208 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 354 | $6K |
| 31720 | <1% | 50 | $6K | |
| 84703 | <1% | 1,035 | $6K | |
| 97161 | <1% | 161 | $6K | |
| 85027 | <1% | 1,092 | $5K | |
| 86140 | <1% | 1,603 | $5K | |
| 76536 | <1% | 69 | $5K | |
| 83655 | <1% | 457 | $5K | |
| 87807 | <1% | 430 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 147 | $4K |
| 83540 | <1% | 1,084 | $4K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 279 | $4K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 42 | $4K |
| 83550 | <1% | 772 | $4K | |
| 85651 | <1% | 1,369 | $4K | |
| 83525 | <1% | 401 | $4K | |
| 87660 | <1% | 238 | $3K | |
| 97014 | <1% | 499 | $3K | |
| 87480 | <1% | 239 | $3K | |
| 80069 | <1% | 1,031 | $3K | |
| 70486 | <1% | 45 | $3K | |
| 86308 | <1% | 638 | $3K | |
| 87510 | <1% | 239 | $3K | |
| 74022 | <1% | 41 | $2K | |
| 0012A | <1% | 90 | $2K | |
| 82950 | <1% | 664 | $2K | |
| 76641 | <1% | 44 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,419 | $2K |
| 71250 | <1% | 83 | $2K | |
| 96367 | <1% | 90 | $2K | |
| 0011A | <1% | 92 | $2K | |
| 82248 | <1% | 380 | $2K | |
| 72141 | <1% | 12 | $2K | |
| 86665 | <1% | 47 | $2K | |
| 76642 | <1% | 40 | $1K | |
| 73090 | <1% | 29 | $1K | |
| 82105 | <1% | 110 | $1K | |
| 51702 | <1% | 42 | $1K | |
| 93880 | <1% | 26 | $1K | |
| 87070 | <1% | 204 | $1K | |
| 82247 | <1% | 276 | $1K | |
| 83001 | <1% | 86 | $1K | |
| 80076 | <1% | 215 | $1K | |
| 97032 | <1% | 168 | $1K | |
| 76770 | <1% | 13 | $1K | |
| 86769 | <1% | 28 | $1K | |
| 82150 | <1% | 190 | $1K | |
| 84403 | <1% | 52 | $965.73 | |
| 86481 | <1% | 14 | $911.70 | |
| 82677 | <1% | 43 | $874.50 | |
| 86765 | <1% | 70 | $845.68 | |
| 81003 | <1% | 546 | $840.90 | |
| 82397 | <1% | 59 | $770.72 | |
| 70496 | <1% | 12 | $684.73 | |
| 86336 | <1% | 43 | $668.74 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 110 | $637.07 |
| 85007 | <1% | 208 | $626.02 | |
| 82565 | <1% | 172 | $582.78 | |
| 73140 | <1% | 14 | $570.80 | |
| 90686 | <1% | 42 | $557.80 | |
| 73080 | <1% | 12 | $555.58 | |
| 87205 | <1% | 181 | $555.16 | |
| 86663 | <1% | 42 | $537.69 | |
| 73590 | <1% | 13 | $433.46 | |
| 97016 | <1% | 56 | $428.17 | |
| 82043 | <1% | 154 | $427.06 | |
| A9270 | Non-covered item or service | <1% | 9,119 | $420.43 |
| 88304 | <1% | 13 | $394.56 | |
| 87210 | <1% | 105 | $393.05 | |
| 36592 | <1% | 10,875 | $389.79 | |
| 84100 | <1% | 175 | $361.05 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,994 | $276.86 |
| 84520 | <1% | 85 | $236.74 | |
| 82951 | <1% | 34 | $234.46 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,284 | $171.37 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,261 | $167.08 |
| 82947 | <1% | 64 | $161.12 | |
| 84146 | <1% | 15 | $137.23 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,149 | $113.20 |
| 82270 | <1% | 66 | $111.48 | |
| 87184 | <1% | 13 | $92.84 | |
| 80305 | <1% | 13 | $92.65 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,175 | $84.05 |
| 96376 | <1% | 1,673 | $71.07 | |
| 82746 | <1% | 12 | $66.55 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,532 | $66.13 |
| 84550 | <1% | 28 | $64.67 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 191 | $45.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,563 | $42.02 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,389 | $30.43 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,243 | $29.22 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 510 | $22.28 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,769 | $18.67 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 921 | $13.96 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,162 | $12.51 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 688 | $12.40 |
| 94760 | <1% | 665 | $10.63 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 417 | $10.28 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 257 | $9.05 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 181 | $8.25 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,338 | $4.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 736 | $1.35 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 295 | $1.22 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 244 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 568 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 24 | $0.00 |
| 90715 | 0% | 628 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 195 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 62 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 38 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 62 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 46 | $0.00 |
| 84145 | 0% | 53 | $0.00 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 28 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 483 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 150 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 244 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 283 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 85 | $0.00 |
| 94761 | 0% | 89 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 19 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 13 | $0.00 |
| 80050 | General health panel | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHESTER, BEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Forrest County General Hospital | Hattiesburg, MS | $81.63M |
| Forrest County General Hospital | Columbia, MS | $9.51M |
| Walthall General Hospital | Tylertown, MS | $6.16M |
| Forrest County General Hospital | Prentiss, MS | $3.80M |
| Forrest County General Hospital | Poplarville, MS | $3.74M |
| Forrest County General Hospital | Poplarville, MS | $2.80M |
| Forrest County General Hospital | Picayune, MS | $2.76M |
| Forrest County General Hospital | Richton, MS | $1.58M |
| Forrest County General Hospital | Richton, MS | $1.36M |
| Forrest County General Hospital | Columbia, MS | $1.03M |
| Walthall General Hospital | Tylertown, MS | $953K |
| Forrest General Hospital | Hattiesburg, MS | $850K |
| Forrest County General Hospital | Poplarville, MS | $253K |
| FGH Physician Billing | Hattiesburg, MS | $224K |
| Forrest County General Hospital | Prentiss, MS | $204K |
| Forrest County General Hospital | Picayune, MS | $65K |
| FGH Trauma Surgery Clinic | Hattiesburg, MS | $47K |
| Forrest County General Hospital | Poplarville, MS | $22K |
| Forrest County General Hospital | Richton, MS | $18K |
| Walthall General Hospital | Tylertown, MS | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.